Abstract:BACKGROUND: Sufficient dose of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen may be an ideal treatment option for renal transplant recipients, and the regimen has been widely used in clinic due to its low nephrotoxicity, few adverse reactions and strong immunosuppressive effects. OBJECTIVE: To investigate the efficacy and safety of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen in renal transplantation patients with the control of mycophenolate mofetil combined with standard-dose tacrolimus and corticosteroid. METHODS: A total of 210 patients receiving a single-organ renal al ograft were randomly divided into standard-dose tacrolimus group (n=104) and low-dose tacrolimus group (n=106). Individual patients were treated for 12 months. The primary efficacy endpoints were the chronic al ograft damage index and glomerular filtration rate at 12 months after transplantation. The secondary efficacy end points mainly included the acute rejection rate, treatment failure rate, and the survival rate of patient and transplant kidney. The safety parameters such as new onset of post-transplantation diabetes mel itus, hypertension and hyperlipidemia were also evaluated. RESULTS AND CONCLUSION: The vast majorities of patients were administrated with sufficient dose of mycophenolate mofetil (1.5 g/d or above) in two groups. The majority of the patients in standard-dose tacrolimus group had the mean trough level below the protocol-defined, which led to the similar mean trough level between standard-dose and low-dose tacrolimus group. These could also confirm that the regimen of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid had been wildly accepted and used by clinicians. The efficacy and safety of two groups were similar. The mean chronic al ograft damage index of the renal pathological changes at 12 months after transplantation in standard-dose and low-dose tacrolimus group were 1.82 and 2.13 respectively (P=0.081 3), the mean glomerular filtration rates were 77.08 mL/min and 80.12 mL/min (P=0.794 9), acute rejection rates were 2.6% and 5.2% (P=0.681 2), and the survival rates of patients and transplant kidney were 100% and 99.1% (P=1.000 0). The rates of new onset of post-transplantation diabetes mel itus in the standard-dose and low-dose tacrolimus group were 2.9% and 1.9%, and the rates of hyperlipidemia were 2.9% and 3.8%, respectively. For the regimen of mycophenolate mofetil combined with tacrolimus and corticosteroid, the utilization of sufficient dose of mycophenolate mofetil could reduce the dose of tacrolimus, thereby significantly reducing the nephrotoxicity, hyperlipidemia and new onset of post-transplantation diabetes mel itus caused by tacrolimus and achieving a good balance of efficacy and toxicity when maintaining a strong immune inhibition and reducing the acute rejection incidence successful y.

The Use of CsA after Combined Liver-Intestine Transplantation

Clinical Uses of Mycophenelate Mofetil and Cyclosporin A in Patients after Liver Transplantation

Influence of Liver Nonparenchymal Cell Infusion Combined with Cyclosporin A on Rejection of Rat Small Bowel Transplantation.

Effects of Combined Immune Therapy on Survival and Th1/Th2 Cytokine Balance in Rat Orthotopic Liver Transplantation

Study of Different Immunotherapy Plans in the Induction of Immune Tolerance in Orthotopic Liver Transplantation in the Rat

The Effect of CsA and rIL-2 on T Lymphocyte Subsets in Rat Peripheral Blood Following Orthotopic Liver Transplantation

Structural Shifts in the Intestinal Microbiota of Rats Treated with Cyclosporine A after Orthotropic Liver Transplantation.

Effect of Combined Immune Therapy on Histology of Allograft and Th1/Th2 Cytokine Profile in Rat Orthotopic Liver Transplantation

Strong Additive Effect of Calcitriol and Cyclosporine A on Lymphocyte Proliferation in Vitro and Rat Liver Allotransplantations in Vivo

Treatment of Organ Transplant Rejection with Low Doses of CsA and CTLA4-Ig

Application of Immunosuppressant Protocol with Low Concentration of Cyclosporine A in Patients with Renal Transplantation

Cost-effectiveness Analysis of Chinese CsA and Import CsA in Patients with Liver Transplantation

[Effect of Anti-Icos Monoclonal Antibody Combined with Low-Dose CsA on Chronic Rejection of Heart Grafts in Rats].

Combined Use of MMF with Low Dosage of Cyclosporine A in Renal Transplantation

Using Tacrolimus,mycophenolate and Senipen for No-Hormone Immunosuppressive Therapy after Liver Transplantation

Cyclosporine A and Tacrolimus Combined with Enteric-Coated Mycophenolate Sodium Influence the Plasma Mycophenolic Acid Concentration - a Randomised Controlled Trial in Chinese Live Related Donor Kidney Transplant Recipients

Cost- Effectiveness Analysis of 3 Immunosuppressants in the Treatment of Liver Transplantation Recipients

Therapeutic Effects of Cyclosporine A on the Rejection of Xenogenic Hepatocyte Transplantation

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Study on Blood Level Monitoring of CsA for Liver Transplantation Patients

The Clinical Value of Enzyme-Multiplied Immunoassay Technique Monitoring the Plasma Concentrations of Cyclosporine A after Renal Transplantation.